<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03415061</url>
  </required_header>
  <id_info>
    <org_study_id>20184334</org_study_id>
    <nct_id>NCT03415061</nct_id>
  </id_info>
  <brief_title>Effect of Intranasal Insulin on POD</brief_title>
  <official_title>Does Intranasal Insulin Administration Reduce the Incidence of Delirium After Cardiac Surgery?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hiroaki Sato, MD., PhD.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Decline in cognitive function after surgery occurs most commonly in older patients and
      patients undergoing major surgeries, such as heart surgery. Postoperative Delirium (POD) is
      an acute disturbance in attention, awareness and cognition. The cause of POD are not fully
      understood. Insulin given intravenously during heart surgery has been shown to preserve short
      and long-term memory function after the operation. Animal study showed that insulin given via
      the nose (intranasal insulin) preserves memory function after exposing to anesthesia
      suggesting that intranasal insulin also could be a therapeutic option POD.

      This study is designed to examine the effect intranasal insulin on POD. The goal is to
      investigate whether administration of intranasal insulin during and after heart surgery
      reduces the incidence of POD.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 1, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Confusion Assessment method for the ICU</measure>
    <time_frame>Up to 7 days after surgery</time_frame>
    <description>Postoperative Delirium is assessment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">418</enrollment>
  <condition>Delirium</condition>
  <condition>Heart Diseases</condition>
  <arm_group>
    <arm_group_label>Intranasal Insulin 40 IU</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 IU of Humulin-R via nose Before surgery and everyday after surgery up to postoperative day 7</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intranasal Normal Saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Normal Saline via nose Before surgery and everyday after surgery up to postoperative day 7</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regular Insulin, Human 100 UNT/ML</intervention_name>
    <description>40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.</description>
    <arm_group_label>Intranasal Insulin 40 IU</arm_group_label>
    <other_name>Humulin R</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Normal Saline Flush, 0.9% Injectable Solution</intervention_name>
    <description>Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery</description>
    <arm_group_label>Intranasal Normal Saline</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        â€¢elective open heart surgery requiring cardiopulmonary bypass

        Exclusion Criteria:

          -  inability to provide informed consent

          -  allergy to insulin

          -  pregnancy

          -  mother tongue other than English or French
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Thomas Schricker, M.D., PhD.</last_name>
    <phone>5149341934</phone>
    <email>thomas.schricker@mcgill.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hiroaki Sato, M.D., PhD.</last_name>
    <phone>5149341934</phone>
    <email>hiroaki.sato2@mcgill.ca</email>
  </overall_contact_backup>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2018</study_first_submitted>
  <study_first_submitted_qc>January 23, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 30, 2018</study_first_posted>
  <last_update_submitted>January 23, 2018</last_update_submitted>
  <last_update_submitted_qc>January 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>Hiroaki Sato, MD., PhD.</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Delirium</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

